Atea Pharmaceuticals Inc (AVIR) USD0.001

- Add to watchlist
- This stock can be held in a




Business summary
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The Company is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The Company is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. It is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The Company is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
Contact details
Important dates
General stock information
- Short code:
- AVIR
- ISIN:
- US04683R1068
- Market cap:
- $712.69 million
- Shares in issue:
- 83.26 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.